Clinica Luganese Moncucco   Report issue

Academic/Hospital Phase 3
Founded: Lugano Switzerland (1905)

Organization Overview

First Clinical Trial
2018
NCT03662360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Clinica Luganese Moncucco

Active Ingredients

Drugs in Phase 3 Trials (1)

enoxaparin (lovenox) (1 trial)

Drugs in Other Trials (1)

lavender (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Embolism (Phase 3)

Pulmonary Embolism (Phase 3)

Thrombosis (Phase 3)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2